Cerebrolyisin
ApprovedSmall molecule
Cerebrolyisin is one of 14 small molecule programs targeting Aphasia. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Aphasia
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Namenda
AbbVieApproved
Keppra
UCBApproved
Piracetam
UCBApproved
Levodopa/carbidopa
Orion Corporation, Orion PharmaPhase 3
Lexapro
AbbViePhase 2
Cerebrolyisin
YYonsei University
Approved
Neflamapimod
EEIP Pharma Inc
Phase 2
Inderal
WWyeth-Lederle Vaccines
Phase 1
Reminyl
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cerebrolyisin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- YYonsei University